芦可替尼乳膏2023中国上市信息以及价格？

China listing information

It is understood that it is not yet on the market in China, and patients cannot purchase this drug in domestic pharmacies and pharmacies. The specific domestic launch time is not yet clear.

1. Opzelura cream is suitable for treating mild to moderate atopic dermatitis (AD) patients over 12 years old, and vitiligo patients over 12 years old. A box shipped from Hong Kong costs about $20,700.

2. The reference price of Yaopin International Ruxolitinib Ointment 30mg is about 400 per box.

Purchase channels

Since this drug is currently not available in China, patients can choose ruxolitinib cream that is available overseas. The specific purchasing methods are as follows:

1. Purchase by yourself: Patients can go overseas to purchase by themselves, but this trip is long and expensive, so it is recommended to consider it carefully.

2. Choose regular overseas medical service institutions: such as Medical Travel, which is a professional cross-border medical service company. Purchasing medicines through this method is relatively fast, and patients can receive medicines at home, which is cost-effective. On the other hand, signing a drug purchase contract with patients can ensure the quality of medicines.

Due to the impact of foreign exchange rate fluctuations, drug prices are not fixed. Please consult the Medical Companion Travel Service for specific drug prices and drug purchase procedures.

1. Serious infections: Infections caused by invasive fungi, bacteria, mycobacteria, viruses, or other pathogens have been reported in patients receiving oral Janus kinase inhibitors. Serious lower respiratory tract infections have been reported during the clinical development program of topical ruxolitinib. Therefore, ruxolitinib cream should be avoided in patients with active severe infections.

Patients should be closely monitored for symptoms and signs of suspected infection during medication. If symptoms of infection occur, treatment should be discontinued promptly.

2. In clinical trials of oral Janus kinase inhibitors for the treatment of inflammatory diseases, higher rates of all-cause mortality, including sudden cardiovascular death, were observed. Therefore, before starting or continuing treatment with OPZELURA, the use should be determined under the evaluation of a physician.

Recommended related articles: